Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15255300 | 0.85 | ACHE (0.42) | ACHEALDH1A1CYP3A4L3MBTL1HPGD | |
| SCHEMBL11996637 | 0.83 | L3MBTL1 (0.47) | MRGPRX4ACHEALDH1A1L3MBTL1HPGD | |
| SCHEMBL8832399 | 0.82 | CYP17A1 (0.45) | ALDH1A1CYP3A4MEN1KMT2AFFAR1 | |
| SCHEMBL2475470 | 0.82 | MEN1 (0.48) | ALDH1A1L3MBTL1HPGDMEN1KMT2A | |
| SCHEMBL30802160 | 0.82 | ACHE (0.52) | ACHEALDH1A1CYP3A4L3MBTL1HPGD | |
| SCHEMBL11890520 | 0.82 | ACHE (0.52) | ACHEALDH1A1CYP3A4L3MBTL1HPGD | |
| SCHEMBL12773618 | 0.81 | ALDH1A1 (0.35) | MRGPRX4ACHEALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL29601399 | 0.80 | HPGD (0.50) | MRGPRX4ACHEALDH1A1L3MBTL1HPGD | |
| SCHEMBL13905218 | 0.80 | MRGPRX4 (0.48) | MRGPRX4ACHEALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL130839 | 0.80 | KDM1A (0.51) | MRGPRX4ACHEALDH1A1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843856-A | KRAS G12C inhibitor | 米拉蒂治疗股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-9102871-B2 | Liquid crystal compound showing negative dielectric anisotropy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-11 | — | — | US | disclosed |
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130277610-A1 | LIQUID CRYSTAL COMPOUND SHOWING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
| EP-2314586-A1 | 2-Acylaminothiazole derivative or salt thereof | Astellas Pharma Inc. (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-1731493-B1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORP (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7265114-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265114-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1731493-A1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORPORATION (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | MRGPRX4 1166/4885ACHE 4868/4885ALDH1A1 2060/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MRGPRX4 2008/4885ACHE 4413/4885ALDH1A1 4407/4885 |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | MRGPRX4 2432/4885ACHE 2637/4885ALDH1A1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.